Orchestra BioMed Holdings (OBIO) Other Gross PP&E Adjustments (2022 - 2026)
Orchestra BioMed Holdings (OBIO) reported Other Gross PP&E Adjustments of $2.2 million for Q1 2026, up 164.77% year-over-year from $843000.0 in Q1 2025, and up 20.65% on a QoQ basis from $1.8 million in Q4 2025.
Orchestra BioMed Holdings (OBIO) has 5 years of Other Gross PP&E Adjustments data on file, last reported at $2.2 million in Q1 2026.
- Quarterly Other Gross PP&E Adjustments rose 164.77% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 164.77% YoY) and the FY2025 annual result came in at $1.8 million, up 216.78% from the prior year.
- Other Gross PP&E Adjustments advanced to $2.2 million in Q1 2026 per OBIO's latest filing, from $1.8 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $2.2 million in Q1 2026 and bottomed at -$1.6 million in Q4 2022.
- The 5-year median for Other Gross PP&E Adjustments is $805500.0 (2023), against an average of $774357.1.
- Peak annual rise in Other Gross PP&E Adjustments reached 1034.04% in 2024, while the deepest fall reached 23.96% in 2024.
- Tracing OBIO's Other Gross PP&E Adjustments over 5 years: stood at -$1.6 million in 2022, then jumped by 147.06% to $768000.0 in 2023, then slipped by 23.96% to $584000.0 in 2024, then surged by 216.78% to $1.8 million in 2025, then increased by 20.65% to $2.2 million in 2026.
- Per Business Quant, the three latest OBIO Other Gross PP&E Adjustments figures stand at $2.2 million (Q1 2026), $1.8 million (Q4 2025), and $1.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Orchestra BioMed Holdings | 245.24 Mn | 255.02 Mn | 78,000.00 | 2.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.23 Mn |
| Mar 31, 2026 | 2.23 Mn |
| Dec 31, 2025 | 1.85 Mn |
| Dec 31, 2025 | 1.85 Mn |
| Sep 30, 2025 | 1.49 Mn |
| Sep 30, 2025 | 1.49 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | 843,000.00 |
| Mar 31, 2025 | 843,000.00 |
| Dec 31, 2024 | 584,000.00 |
| Dec 31, 2024 | 584,000.00 |
| Sep 30, 2024 | 759,000.00 |
| Sep 30, 2024 | 759,000.00 |
| Jun 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 1.05 Mn |
| Mar 31, 2024 | 878,000.00 |
| Mar 31, 2024 | 878,000.00 |
| Dec 31, 2023 | 768,000.00 |
| Dec 31, 2023 | 768,000.00 |
| Sep 30, 2023 | 634,000.00 |
| Sep 30, 2023 | 634,000.00 |
| Jun 30, 2023 | 454,000.00 |
| Jun 30, 2023 | 454,000.00 |
| Mar 31, 2023 | -94,000.00 |
| Mar 31, 2023 | -94,000.00 |
| Dec 31, 2022 | -1.63 Mn |
| Dec 31, 2022 | -1.63 Mn |